Maria Polozova

Mrs. Maria Polozova


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GOGrainne O'Brien
Grainne O'Brien
MKMałgorzata Emilia Kamuda
Małgorzata Emilia Kamuda
LCLourdes Cruz-Garcia
Lourdes Cruz-Garcia
MPMaria Polozova
Maria Polozova
ATAles Tichy
Ales Tichy
Christophe BadieChristophe Badie
Christophe Badie
Cancer and ionizing radiation exposure are associated with inflammation. To identify a set of radiation-specific signatures of inflammation-associated genes in the blood of partially exposed radiotherapy patients, differential expression of 249 inflammatory genes was analyzed in blood samples from cancer patients and healthy individuals. The gene expression analysis on a cohort of 63 cancer patients (endometrial, head and neck, and prostate cancer) before and during radiotherapy (24 h, 48 h, ~1 week, ~4–8 weeks, and 1 month after the last fraction) identified 31 genes and 15 up- and 16 down-regulated genes. Transcription variability under normal conditions was determined using blood drawn on three separate occasions from four healthy donors. No difference in inflammatory expression between healthy donors and cancer patients could be detected prior to radiotherapy. Remarkably, repeated sampling of healthy donors revealed an individual endogenous inflammatory signature. Next, the potential confounding effect of concomitant inflammation was studied in the blood of seven healthy donors taken before and 24 h after a flu vaccine or ex vivo LPS (lipopolysaccharide) treatment; flu vaccination was not detected at the transcriptional level and LPS did not have any effect on the radiation-induced signature identified. Finally, we identified a radiation-specific signature of 31 genes in the blood of radiotherapy patients that were common for all cancers, regardless of the immune status of patients. Confirmation via MQRT-PCR was obtained for BCL6, MYD88, MYC, IL7, CCR4 and CCR7. This study offers the foundation for future research on biomarkers of radiation exposure, radiation sensitivity, and radiation toxicity for personalized radiotherapy treatment.

11 June 2026 in Radiation Research
Verified
Journal Article
Closed access
PDF file
MPMaria Polozova
Maria Polozova
LCLourdes Cruz-Garcia
Lourdes Cruz-Garcia
SGShanaz A. Ghandhi
Shanaz A. Ghandhi
SKSalan Preet Kaur
Salan Preet Kaur
GGGuy Garty
Guy Garty
CBChristophe Badie
Christophe Badie
Rapid molecular biodosimetry may support radiation exposure assessment during mass casualty or mixed-field radiological incidents, but how gene expression responses vary across radiation qualities and dose rates remains incompletely characterized. Gene expression biodosimetry, including transcript-variant-aware measurements resulting from alternative splicing, may improve sensitivity for determining radiation quality and dose rate. We profiled nine radiation-responsive genes (AEN, APOBEC3H, DDB2, EDA2R, FDXR, PCNA, RPS27L, TRIAP1, ZMAT3) and six FDXR transcript variants using custom 384-well microfluidic RT-qPCR array cards (TaqMan Low Density Array, TLDA) of ex vivo leukopak-derived samples (leukocyte-enriched blood products) from three healthy donors, harvested 24 h after irradiation. Samples received an acute exposure of X rays (0.1-4 Gy), a protracted exposure of X rays (2 Gy at 0.1, 0.01, 0.004 Gy‧min21), and a mixed neutron field exposure with approximately 81% neutrons and 19% concomitant γ-rays (0.1-2 Gy at 0.6-1 Gy‧h21). In a separate experiment, gene expression of leukopaks was concordant with whole blood responses for FDXR and CDKN1A, with FDXR exceeding a 30-fold induction after exposure to 4 Gy of X rays. In the TLDA dataset, all targets were upregulated in a dose-dependent manner. Over the range of 0.1-1 Gy, neutrons elicited higher induction than X rays for APOBEC3H, DDB2, and FDXR, with convergence at 2 Gy as X-ray responses plateaued. Variant-level analysis showed isoform-specific behavior: FDXR-203 and FDXR-206 mRNA isoforms were induced by neutrons (especially at higher doses), while FDXR-202, FDXR-205, and FDXR-217 responded preferentially to X rays and FDXR-204 was moderately upregulated after X-ray irradiation. After protracted X-ray exposure, most genes were up-regulated with minimal dose-rate effects; AEN was the only target that differed significantly between 0.004 and 0.01 Gy‧min21, and FDXR-202/-204/-205 showed a higher fold change at the lowest dose rate. Analysis of dose-response behavior and derived relative biological effectiveness (RBE) values revealed three patterns when comparing neutrons with X rays. First, FDXR, DDB2 and EDA2R were more responsive to neutrons than to X rays at low doses (0.1–1 Gy), with fold changes increasing faster for neutrons. Depending on the gene, neutrons were equivalent to X-ray doses that were approximately 2–4 times higher, consistent with results reported previously for cytogenetic endpoints. Second, APOBEC3H, FDXR-217, RPS27L, PCNA and FDXR-203 showed similar dose-response behavior after exposure to neutrons and X rays, with occasional plateau differences. Third, AEN, TRIAP1 and the remaining assayed FDXR variants showed high variability and were not studied further here. Overall, several genes showed little discrimination across low dose rates, supporting their use for estimating total dose, while others showed clear differences between radiations of different qualities. Taken together, our results support the further development of multi-gene, variant-resolved approaches for radiation exposure assessment in mixed-field scenarios.